Additionally, while Btz treatment has been utilized and proven effective as a single-agent therapeutic in CTCL, acquired resistance is a known barrier to its efficacy, and recent studies have linked the higher expression of heat shock proteins with acquired resistance to Btz [69,70]. Here, CASC3 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.